TCM
TXG icon

True Capital Management’s 10x Genomics TXG Stock Holding History

True Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$214K Buy
+3,834
New +$179K 0.15% 122

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

True Capital Management's TXG Position: Q1 2023 in Review

True Capital Management opened a new position in 10x Genomics (TXG) in Q1 2023: 3,834 shares worth $214K. The stake represents 0.15% of the portfolio and ranks #122 among its holdings.

258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • True Capital Management held 3,834 shares of 10x Genomics worth $214K as of Q1 2023.
  • 10x Genomics was a new True Capital Management position in Q1 2023.
  • 10x Genomics made up 0.15% of True Capital Management's portfolio in Q1 2023, its #122 holding.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on True Capital Management's 13F filing for Q1 2023, filed 2 May 2023.